How Partnerships and Collaboration Accelerate Medical Innovation

In medical technology, innovation is rarely the result of a single discipline working in isolation.

The most meaningful advances emerge when engineering expertise meets clinical insight, when research meets real-world application, and when technology developers work closely with the organisations that understand the challenges of patient care.

For Oldelft Ultrasound, this principle is central to how we approach research and development.

For decades, we have developed increasingly sophisticated ultrasound transducer technologies by combining expertise in acoustics, electronics, miniaturisation and ASIC development with a deep understanding of the requirements of medical imaging. Today, that approach is increasingly being extended through partnerships with OEMs, research organisations and clinical experts.

Because the challenges facing medical imaging are too complex for any one organisation to solve alone.

From technology development to clinical need

Innovation in medical technology begins with a problem worth solving.

That problem may come from an engineer identifying a technological limitation, an OEM seeking a new imaging capability, or a clinician identifying a challenge in diagnosis or treatment.

The real opportunity emerges when these perspectives come together.

A clinician understands the workflow, anatomy and practical demands of a procedure. An engineer understands what can be achieved within the physical and technical constraints of a device. An OEM understands system integration, manufacturing requirements and the pathway to commercial deployment.

Bringing these perspectives together early can fundamentally change the development process.

Instead of developing technology first and determining its application later, multidisciplinary collaboration enables teams to define the clinical requirement, technical parameters and intended use together.

This creates a more focused path from concept to prototype, validation and ultimately clinical application.

Research into healthcare innovation has similarly demonstrated that collaboration between clinicians and engineers can accelerate iteration and help translate unmet clinical needs into usable medical devices.

The value of specialised expertise

Advanced ultrasound is an excellent example of why collaboration matters.

Modern transducers must balance multiple competing requirements: image quality, miniaturisation, acoustic performance, electronics, ergonomics, mechanical articulation and compatibility with imaging systems.

As devices become smaller and more sophisticated, those challenges become increasingly interconnected.

“Oldelft's R&D capabilities span transducer technology, miniaturisation, acoustics and ASIC development. Its 4D ultrasound platform, for example, is built around an in-house designed ASIC and a scalable architecture for real-time 3D imaging,” says Michiel Baas, R&D Manager at Oldelft Ultrasound, in Delft Netherlands.

But technical capability alone does not determine whether an innovation will make a meaningful difference.

Understanding how that technology will be used is equally important.

“This is why long-term collaboration with medical technology companies and OEM partners is such an important part of Oldelft's approach. Rather than offering a one-size-fits-all technology, Oldelft works with partners to develop tailor-made transducer solutions for specific applications and system requirements,” Michiel added.

Collaboration can shorten the distance between an idea and its application

One of the greatest advantages of a strong R&D partnership is the ability to bring different stages of innovation closer together.

Research can inform engineering.

Engineering can inform clinical feasibility.

Clinical feedback can refine the design.

And OEM expertise can help determine how the technology can ultimately be integrated into a medical imaging system.

This creates an iterative development cycle rather than a linear one.

The result can be faster learning, earlier identification of technical constraints and a clearer understanding of what is required for successful clinical implementation.

For medical devices, this matters enormously. Clinical investigations and performance studies are fundamental to demonstrating the safety and performance of medical technologies, making the connection between development and clinical evaluation particularly important.

SEISMICIHI: collaboration in action

Oldelft's participation in the SEISMICIHI research consortium illustrates this approach.

The five-year initiative, supported by EUR 23.5 million in public funding from the Innovative Health Initiative, brings together multiple organisations to advance minimally invasive neurosurgery through the integration of surgical techniques and advanced imaging.

Within the consortium, Oldelft is developing an advanced 4D ultrasound probe designed to provide real-time visualisation of the brain during cryoablation treatment of brain tumours.

But Oldelft is not developing the technology in isolation.

Oldelft is leading probe development and working with US4US to integrate the technology into the broader imaging system, while Erasmus MC contributes expertise in imaging and clinical workflow. The ultimate objective is to test the technology in a clinical environment during the project.

This is precisely where collaboration becomes more than a business relationship.

Each partner contributes a different capability to the same innovation challenge.

Oldelft provides ASIC and transducer technology.

US4US contributes system knowledge and integration capabilities.

Erasmus MC brings imaging and clinical workflow expertise.

Together, those capabilities create possibilities that would be much harder to achieve independently.

From supplier relationships to innovation partnerships

There is an important distinction between supplying technology and developing technology together.

A traditional supplier relationship may begin with a defined specification: a customer needs a component, and a supplier delivers it.

An innovation partnership begins earlier.

The problem itself may still be evolving.

The technical requirements may not yet be fully defined.

And neither partner may know exactly what the final solution will look like.

That uncertainty is not a weakness. It is often where innovation begins.

“Oldelft's partnership model is built around this principle. The company actively works with organisations that have innovative ultrasound propositions requiring advanced transducer technology, offering expertise across 4D imaging, acoustics, ASICs and miniaturisation.

The objective is not simply to deliver a component.

It is to work together towards a solution,” says Stefan Roggeveen, Commercial Manager at Oldelft Ultrasound.

The ecosystem is becoming part of the R&D strategy

Medical technology is becoming increasingly interdisciplinary.

Imaging, electronics, software, artificial intelligence, materials science, robotics and minimally invasive techniques are converging.

As these technologies intersect, the expertise required to develop them becomes broader.

This is why collaborative R&D models are becoming increasingly important across the medical technology ecosystem. Even regulatory organisations such as the U.S. FDA have established dedicated programs to foster partnerships between industry, academia, government, patient organisations and other stakeholders to advance medical-device innovation and regulatory science.

The implication is clear: the future of medical innovation will not be defined only by what an individual company can develop internally.

It will also be defined by who it can collaborate with, how effectively those capabilities can be combined, and how quickly ideas can move between disciplines.

Innovation is ultimately about people working across boundaries

Technology may be at the centre of medical innovation, but collaboration is what connects the technology to its purpose.

The engineer sees the technical challenge.

The clinician sees the clinical need.

The researcher sees what might be possible.

The OEM sees how the technology can become part of a complete system.

And ultimately, the patient is the reason those perspectives need to come together.

At Oldelft Ultrasound, our R&D philosophy is therefore not simply about developing more advanced transducers.

It is about creating the right environment for innovation to happen, combining specialised engineering expertise with long-term partnerships, clinical insight and a willingness to solve difficult problems together.

Because the next breakthrough in medical imaging may not come from one laboratory, one company or one discipline.

It may come from what becomes possible when the right partners work on the problem together.

Innovation accelerates when expertise is shared, perspectives are combined and technology is developed with its real-world purpose in mind.

About Oldelft

Oldelft Ultrasound is a medical diagnostic company, specialized in the development, manufacture and service of innovative Ultrasound transducers. Oldelft Ultrasound is an OEM supplier to the Ultrasound equipment companies worldwide. Oldelft is especially well-known for its TEE (Trans Esophageal Echocardiography) transducers, and specialists in miniaturization of transducers. Based out of Delft, in The Netherlands, Oldelft is part of the steute Technologies group.

Oldelft - Commercial Contact - Stefan Roggeveen - info@oldelft.nl